Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Caris Life Sciences Q3 2026 Results: Net Income $15.2M, Down 37.3% YoY

Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.

Watch the Caris Life Sciences, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue275.4216.8
Profit before tax16.924.3
Net income15.224.3
EPS (diluted, $ a share)$0.05$0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-37.3%
Revenue, year on year+27.0%
Operating margin7.0%
Source

10-Q filed with the SEC, NASDAQ: CAI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Caris Life Sciences, Inc.: key numbers

Share price
$21.00Close, Nov 16
Market cap
$6.02B
Shares outstanding
286.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Caris Life Sciences, Inc.

All →
4:13 PM ET 8-K
Financial Results

Caris Life Sciences Financial Results

Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.

Term
Q3 2026

“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”

David Dean Halbert, Founder, Chairman and CEO
4:40 PM ET 8-K
Investor Presentation

Caris Life Sciences Investor Presentation

Caris Life Sciences announced that its management team will use a formal investor presentation for meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference beginning September 14, 2026. The presentation will be made available on the company's investor relations website.

Counterparty
Morgan Stanley 24th Annual Global Healthcare Conference

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.